The quest for fragile X biomarkers
Conclusions
Bench-to-bedside plans for fragile X syndrome are severely limited by the lack of validated outcome measures. The reviewed candidate biomarkers are at early stages of validation and deserve further investigation.
Source: Molecular and Cellular Pediatrics - Category: Cytology Source Type: research
More News: Autism | Clinical Trials | Cytology | Disability | Fragile X Syndrome | Genetics | Pediatrics